Oncology

Following reports last week of a bid, it has now been confirmed that the Canadian company Valeant Pharmaceuticals International Inc will buy Provenge-maker Dendreon.

The results published in the Journal of Thoracic Oncology found that the response rate to tyrosine kinase inhibitor therapy was significantly higher in classic vs rare EGFR mutations.

The concept of pathways is the most widely adopted solution to reduce the high cost of cancer care, according to Bruce Feinberg, DO, vice president and chief medical officer of oncology at Cardinal Health Specialty Solutions.

For patients with lung or colorectal cancer, bevacizumab treatment patterns and healthcare costs varied by the setting of treatment initiation (physician office vs hospital outpatient).

St. Jude Children's Research Hospital investigators have discovered inherited genetic variations associated with rapid hearing loss in young cancer patients treated with the drug cisplatin, as published in Nature Genetics.

Interim analysis during a phase 3 study of Ixazomib in patients with relapsed or refractory multiple myeloma found that the drug improved the primary endpoint of progression-free survival.

The drug has been approved for treatment-naive patients who are ineligible for transplant.

The 3D breast imaging system, developed at the University of Rochester, is currently approved for diagnosing cancer in women who have signs or symptoms of the disease, or who have abnormal findings after a standard screening mammogram.

Following an announcement that Medicare would cover preventive low dose computes tomography for lung cancer screening, CMS released a final national coverage determination today that includes details on eligibility criteria.

A study published in the journal Lancet Oncology, conducted by the Institute of Cancer Research (ICR), London, provides evidence for the value of introducing abiraterone prior to chemotherapy in these patients.

The industry-academic partnership is expected to boost clinical trials on investigational drugs and outcomes research, in gynecological cancers.

With several of it's blockbusters going off-patent soon, Pfizer is looking at new avenues for expanding it's revenue.

After nearly 6 years overseeing public health initiatives, Margaret Hamburg, MD, commissioner of the FDA will be stepping down, according to various sources.

A comprehensive study published in the Journal of Clinical Oncology found that colorectal cancer survivors who smoke cigarettes were at more than twice the risk of death than non-smoking survivors.

Although African Americans have had lower colon cancer survival rates over the past 2 decades compared with white patients, researchers at the Stanford University School of Medicine have found evidence-based care can remove the racial disparity.

In his blog post on FDAVoice, Peter Lurie MD, MPH, associate FDA commissioner for public health strategy and analysis, announced the introduction of a draft form and a draft guideline that can be used by a physician to request access to an experimental drug or biological product that is still under development.

The report, according to ASCO, delineates responsibilities of different stakeholders towards ensuring responsible data sharing of trial results.

The efficacy of the CDK4/6 inhibitor was demonstrated in 165 postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous treatment for advanced disease.

The study, published in the Journal of Clinical Oncology concluded that the failure rate was low with observation but was decreased significantly with the addition of radiotherapy.

The study identified distinct methylation patterns between the aggressive and benign forms of TNBC, which could provide an improved understanding of disease outcome.

A study published in the Journal of Thoracic Disease digs deep into understanding the assumptions in HEOR studies that evaluate the cost-effectiveness of personalized cancer treatments.

Panelists discuss ways to improve the focus on clinical utility in molecular diagnostics given challenges in the system and needs of patients.

Multiplexed genetic screening for EGFR and ALK gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic NSCLC setting in the United States, researchers report in The Journal of Thoracic Oncology.

With 3 I-O agents have already been approved for metastatic melanoma, 2 from BMS and 1 from Merck, the race for NSCLC has tightened with multiple ongoing clinical trials.

The Canadian company Valeant Pharmaceuticals International Inc has reached an agreement to buy the prostate cancer immunotherapy from Dendreon Corp.